FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported that on March 17, 2009, Dr. Samuel Lynch, president and chief executive officer, entered into a Rule 10b5-1 plan to sell up to a maximum of 12% of his current equity position in the Company over the remainder of the year, assuming certain price targets are reached. The sales are intended to allow Dr. Lynch to gradually diversify a small portion of his holdings over a period of time, as long as certain price thresholds are met. All sales of Company common stock under the plan will be reported through appropriate filings with the Securities and Exchange Commission.
